Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024

Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024

DelveInsight’s, ''Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Carbapenem-Resistant Enterobacteriaceae pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Carbapenem-Resistant Enterobacteriaceae Understanding

Antibiotic resistance is a growing problem. Resistance genes exist for all known antibiotics in use today, and extremely resistant pathogens are becoming more common. Gram-negative bacteria have developed the broadest spectrum of resistance due to multiple structural adaptations and antibiotic degradation enzymes, including expanded spectrum beta-lactamases (ESBL), AmpC cephalosporinases, and carbapenemases. Carbapenemase-producing Enterobacteriaceae (CRE) are of particular concern.

""Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carbapenem-Resistant Enterobacteriaceae pipeline landscape is provided which includes the disease overview and Carbapenem-Resistant Enterobacteriaceae treatment guidelines. The assessment part of the report embraces, in depth Carbapenem-Resistant Enterobacteriaceae commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carbapenem-Resistant Enterobacteriaceae collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Carbapenem-Resistant Enterobacteriaceae. The therapies under development are focused on novel approaches to treat/improve Carbapenem-Resistant Enterobacteriaceae.

Carbapenem-Resistant Enterobacteriaceae Emerging Drugs

Durlobactam: Entasis Therapeutics

Durlobactam (DUR; previously designated ETX2514) is our novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in A. baumannii thus restoring sulbactam’s activity. We are developing SUL-DUR (previously designated ETX2514SUL), a combination of β-lactam antibiotic and a β-lactamase inhibitor for the treatment of serious infections cuased by Acinetobacter, including multidrug-resistant (MDR) strains.

Further product details are provided in the report……..

Carbapenem-Resistant Enterobacteriaceae: Therapeutic Assessment

This segment of the report provides insights about the Carbapenem-Resistant Enterobacteriaceae drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Carbapenem-Resistant Enterobacteriaceae

There are approx. 10+ key companies which are developing the therapies Carbapenem-Resistant Enterobacteriaceae. The companies which have their Carbapenem-Resistant Enterobacteriaceae drug candidates in the most advanced stage, i.e Phase III include Entasis Therapeutics

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Carbapenem-Resistant Enterobacteriaceae pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Carbapenem-Resistant Enterobacteriaceae: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Carbapenem-Resistant Enterobacteriaceae therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Carbapenem-Resistant Enterobacteriaceae drugs.

Carbapenem-Resistant Enterobacteriaceae Report Insights

• Carbapenem-Resistant Enterobacteriaceae Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Carbapenem-Resistant Enterobacteriaceae Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Carbapenem-Resistant Enterobacteriaceae drugs?
• How many Carbapenem-Resistant Enterobacteriaceae drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Carbapenem-Resistant Enterobacteriaceae?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Carbapenem-Resistant Enterobacteriaceae therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Carbapenem-Resistant Enterobacteriaceae and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vedanta Biosciences
• Summit Therapeutics
• SuperTrans Medical
• Entasis Therapeutics
• AGILeBiotics
• Buywork
• Nosopharm

Key Products

• VE707
• SMT-738
• STM-004
• Durlobactam
• ABX-605
• GYROX-2
• NOSO-502